JP2017516104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516104A5 JP2017516104A5 JP2016567654A JP2016567654A JP2017516104A5 JP 2017516104 A5 JP2017516104 A5 JP 2017516104A5 JP 2016567654 A JP2016567654 A JP 2016567654A JP 2016567654 A JP2016567654 A JP 2016567654A JP 2017516104 A5 JP2017516104 A5 JP 2017516104A5
- Authority
- JP
- Japan
- Prior art keywords
- mass spectrometry
- amount
- norendoxifene
- tamoxifen
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 34
- 239000002207 metabolite Substances 0.000 claims 9
- 238000004949 mass spectrometry Methods 0.000 claims 8
- 150000002500 ions Chemical class 0.000 claims 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 6
- 238000000746 purification Methods 0.000 claims 6
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims 5
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 claims 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims 4
- 238000004811 liquid chromatography Methods 0.000 claims 4
- 229960001603 tamoxifen Drugs 0.000 claims 3
- KLPBCGLMGLFHNY-OCOZRVBESA-N 4-[(E)-1-[4-[2-(methylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)\C1=CC=CC=C1 KLPBCGLMGLFHNY-OCOZRVBESA-N 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 230000006920 protein precipitation Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000004885 tandem mass spectrometry Methods 0.000 claims 2
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992214P | 2014-05-12 | 2014-05-12 | |
| US61/992,214 | 2014-05-12 | ||
| PCT/US2015/030419 WO2015175561A1 (en) | 2014-05-12 | 2015-05-12 | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018004851A Division JP6821610B2 (ja) | 2014-05-12 | 2018-01-16 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516104A JP2017516104A (ja) | 2017-06-15 |
| JP2017516104A5 true JP2017516104A5 (enExample) | 2017-07-27 |
| JP6279104B2 JP6279104B2 (ja) | 2018-02-14 |
Family
ID=54367635
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567654A Active JP6279104B2 (ja) | 2014-05-12 | 2015-05-12 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2018004851A Active JP6821610B2 (ja) | 2014-05-12 | 2018-01-16 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2021000689A Pending JP2021073450A (ja) | 2014-05-12 | 2021-01-06 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2023080724A Pending JP2023109874A (ja) | 2014-05-12 | 2023-05-16 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2025018885A Pending JP2025081382A (ja) | 2014-05-12 | 2025-02-07 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018004851A Active JP6821610B2 (ja) | 2014-05-12 | 2018-01-16 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2021000689A Pending JP2021073450A (ja) | 2014-05-12 | 2021-01-06 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2023080724A Pending JP2023109874A (ja) | 2014-05-12 | 2023-05-16 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
| JP2025018885A Pending JP2025081382A (ja) | 2014-05-12 | 2025-02-07 | 質量分析によるタモキシフェンおよびその代謝産物の定量化 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9459267B2 (enExample) |
| EP (2) | EP4220178A3 (enExample) |
| JP (5) | JP6279104B2 (enExample) |
| CN (2) | CN110044998B (enExample) |
| AU (6) | AU2015259294A1 (enExample) |
| BR (1) | BR112016026459B1 (enExample) |
| CA (1) | CA2948823C (enExample) |
| SA (1) | SA516380291B1 (enExample) |
| WO (1) | WO2015175561A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3486648B1 (en) * | 2008-12-24 | 2025-04-30 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
| EP4220178A3 (en) * | 2014-05-12 | 2023-08-16 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
| CN105159539B (zh) * | 2015-09-10 | 2018-06-01 | 京东方科技集团股份有限公司 | 可穿戴设备的触控响应方法、装置及可穿戴设备 |
| US12055518B2 (en) | 2019-10-10 | 2024-08-06 | Regeneron Pharmaceuticals, Inc. | Liquid chromatography-mass spectrometry (LC-MS) methods for analyzing ampholyte lot variation |
| IL295038A (en) | 2020-01-31 | 2022-09-01 | Regeneron Pharma | Use of liquid chromatography and mass spectrometry to characterize oligonucleotides |
| US12105102B2 (en) | 2022-03-30 | 2024-10-01 | University Of Utah Research Foundation | Methods for quantifying insulin-like growth factor-1 and insulin-like growth factor-2 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5119827A (en) * | 1990-09-05 | 1992-06-09 | Board Of Regents, The University Of Texas System | Mechanisms of antiestrogen resistance in breast cancer |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| DK0700521T3 (da) | 1993-05-28 | 2003-09-29 | Baylor College Medicine | Fremgangsmåde og massespektrometer til desorption og ionisering af analysander |
| IES66994B2 (en) * | 1995-12-08 | 1996-02-21 | Bunskellig Limited | A process for analysing a fluid |
| GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| US6600155B1 (en) | 1998-01-23 | 2003-07-29 | Analytica Of Branford, Inc. | Mass spectrometry from surfaces |
| CN1871517A (zh) * | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
| EP2050443B1 (en) * | 2002-12-18 | 2017-05-24 | Besins Healthcare Luxembourg SARL | Reduction of breast density with 4-hydroxy tamoxifen |
| NZ542499A (en) * | 2003-04-01 | 2008-10-31 | Besins Int Lab | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| JP4555779B2 (ja) * | 2003-12-26 | 2010-10-06 | 武田薬品工業株式会社 | 脂質代謝異常症の予測方法 |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| WO2006052921A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US8017403B2 (en) * | 2007-06-14 | 2011-09-13 | Quest Diagnostics Investments Incorporated | Mass spectrometry method for measuring vitamin B6 in body fluid |
| US20090134325A1 (en) * | 2007-11-27 | 2009-05-28 | Goldman Mildred M | Methods for detecting estradiol by mass spectrometry |
| US8916385B2 (en) * | 2007-12-13 | 2014-12-23 | Quest Diagnostics Investments, Inc. | Methods for detecting estrone by mass spectrometry |
| US7834313B2 (en) | 2008-08-08 | 2010-11-16 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for plasma-renin |
| EP3722810A3 (en) * | 2009-02-11 | 2021-01-13 | Caris MPI, Inc. | Molecular profiling of tumors |
| CA2776383C (en) * | 2009-10-06 | 2019-04-30 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of drug-induced cardiotoxicity |
| WO2012119010A2 (en) * | 2011-03-01 | 2012-09-07 | Indiana University Research And Technology Corporation | Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer |
| WO2012167126A1 (en) * | 2011-06-03 | 2012-12-06 | Purdue Research Foundation | Ion generation using modified wetted porous materials |
| EP2822955B1 (en) * | 2012-03-05 | 2017-07-26 | Xavier University | Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer |
| EP2876434A4 (en) * | 2012-07-17 | 2016-05-04 | Snu R&Db Foundation | METHOD FOR IMPROVING THE REPRODUCIBILITY OF A MASS SPECTRUM AND QUANTITATIVE ANALYSIS METHOD THEREWITH |
| CN103494787B (zh) * | 2013-07-22 | 2014-10-29 | 南通广泰生化制品有限公司 | 枸橼酸他莫昔芬滴丸 |
| EP4220178A3 (en) * | 2014-05-12 | 2023-08-16 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
-
2015
- 2015-05-12 EP EP23157017.7A patent/EP4220178A3/en active Pending
- 2015-05-12 WO PCT/US2015/030419 patent/WO2015175561A1/en not_active Ceased
- 2015-05-12 CN CN201910220665.6A patent/CN110044998B/zh active Active
- 2015-05-12 BR BR112016026459-2A patent/BR112016026459B1/pt active IP Right Grant
- 2015-05-12 EP EP15793289.8A patent/EP3143392B1/en active Active
- 2015-05-12 JP JP2016567654A patent/JP6279104B2/ja active Active
- 2015-05-12 US US14/710,311 patent/US9459267B2/en active Active
- 2015-05-12 CA CA2948823A patent/CA2948823C/en active Active
- 2015-05-12 AU AU2015259294A patent/AU2015259294A1/en not_active Abandoned
- 2015-05-12 CN CN201580037630.9A patent/CN106537139B/zh active Active
-
2016
- 2016-10-03 US US15/284,248 patent/US9835606B2/en active Active
- 2016-11-13 SA SA516380291A patent/SA516380291B1/ar unknown
-
2017
- 2017-12-04 US US15/830,812 patent/US10830746B2/en active Active
-
2018
- 2018-01-16 JP JP2018004851A patent/JP6821610B2/ja active Active
- 2018-12-07 AU AU2018275011A patent/AU2018275011A1/en not_active Abandoned
-
2020
- 2020-09-23 AU AU2020239700A patent/AU2020239700B2/en active Active
- 2020-11-09 US US17/093,472 patent/US11428682B2/en active Active
-
2021
- 2021-01-06 JP JP2021000689A patent/JP2021073450A/ja active Pending
-
2022
- 2022-04-20 AU AU2022202628A patent/AU2022202628B2/en active Active
- 2022-08-23 US US17/893,950 patent/US11835505B2/en active Active
-
2023
- 2023-05-16 JP JP2023080724A patent/JP2023109874A/ja active Pending
- 2023-07-07 AU AU2023204389A patent/AU2023204389B2/en active Active
- 2023-10-25 US US18/494,030 patent/US12270803B2/en active Active
-
2024
- 2024-10-09 AU AU2024227191A patent/AU2024227191A1/en active Pending
-
2025
- 2025-02-07 JP JP2025018885A patent/JP2025081382A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516104A5 (enExample) | ||
| JP2018077253A5 (enExample) | ||
| Berg et al. | 13C labelled internal standards—A solution to minimize ion suppression effects in liquid chromatography–tandem mass spectrometry analyses of drugs in biological samples? | |
| Robles-Molina et al. | Multi-residue method for the determination of over 400 priority and emerging pollutants in water and wastewater by solid-phase extraction and liquid chromatography-time-of-flight mass spectrometry | |
| MX2017015229A (es) | Metodos para la cuantificacion espectrometrica de masas de analitos extraidos de un dispositivo de micromuestreo. | |
| JP2011530701A5 (enExample) | ||
| WO2020123319A3 (en) | Methods of using master / copy arrays for spatial detection | |
| JP2013513802A5 (enExample) | ||
| Wu et al. | Simultaneous determination of amantadine, rimantadine and memantine in chicken muscle using multi-walled carbon nanotubes as a reversed-dispersive solid phase extraction sorbent | |
| WO2015184321A3 (en) | Rare molecule detection | |
| JP2013525801A5 (enExample) | ||
| JP2011505013A5 (enExample) | ||
| Zhang et al. | Simultaneous determination of 12 illicit drugs in whole blood and urine by solid phase extraction and UPLC–MS/MS | |
| JP2019503493A5 (enExample) | ||
| JP2011504596A5 (enExample) | ||
| SA516380291B1 (ar) | الحساب الكمي لتاموكسيفين ونواتج أيضه بواسطة القياس الطيفي الكتلي | |
| WO2013184995A8 (en) | Methods and apparatus for performing mass spectrometry | |
| Wong et al. | Advances in rapid detection of SARS-CoV-2 by mass spectrometry | |
| Liu et al. | Matrix effects in the liquid chromatography-tandem mass spectrometry method of analysis | |
| JP2021067524A5 (enExample) | ||
| JIANG et al. | Application of Q-Orbitrap high resolution mass spectrometry to the detection of illegal adulterated antihyperlipidemics in herbal medicines and dietary supplements | |
| MX379918B (es) | Metodos para analisis y resolucion de preparaciones de dianhidrogalactitol y derivados o analogos del mismo. | |
| RU2018104707A (ru) | ИСПОЛЬЗОВАНИЕ МОЛЕКУЛЯРНЫХ МАРКЕРОВ IL-3, IL-33 и IL12ρ40 ДЛЯ ХАРАКТЕРИСТИКИ СТЕПЕНИ ТЯЖЕСТИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ ЧЕЛОВЕКА И МЕТАПНЕВМОВИРУСОМ ЧЕЛОВЕКА | |
| BR112022004390A2 (pt) | Métodos de lc-ms para isotipagem e quantificação de anticorpos | |
| RU2015104248A (ru) | Способ идентификации органических соединений методом хроматр-масс-спектрометрии |